4 July 2024
BELLUSCURA PLC
("Belluscura" or the "Company")
Director/PDMR Shareholding
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that on 3 July 2024, David Poutney, Non-Executive Director of the Company, sold 4,350,000 ordinary shares of 1 penny each ("Ordinary Shares") held in his own name, and 3,800,000 Ordinary Shares were acquired by his self-invested pension plan ("SIPP") with the balance of 550,000 Ordinary Shares being acquired by his wife's, Vivienne Poutney and a person closely associated, SIPP.
Following this transfer, Mr Poutney, and his persons closely associated, remain interested in a total of 14,255,731 Ordinary Shares in the Company, representing 8.53 per cent. of the Company's issued Ordinary Share capital.
For further information please contact:
Belluscura plc | Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman |
|
|
|
SPARK Advisory Partners Limited Nominated Adviser | Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat |
|
|
|
Dowgate Capital Limited Broker | Tel: +44 (0)20 3903 7715 |
Russell Cook / Nicholas Chambers |
|
|
|
MHP Group Financial PR & Investor Relations | Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
Katie Hunt / Matthew Taylor |
|
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | David Poutney (PDMR) | ||||
2 | Reason for notification | |||||
a) | Position / status | Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Belluscura plc | ||||
b) | LEI | 213800BRJQZE56XBPW94 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 each in Belluscura plc ISIN: GB00BD3B8Z11 | ||||
b) | Nature of the transaction | (i) Sale of shares (ii) Purchase of shares in SIPP | ||||
c) | Price(s) and volumes(s) |
| ||||
d) | Aggregated information | n/a | ||||
e) | Date of the transaction | 3 July 2024 | ||||
f) | Place of the transaction | London Stock Exchange |
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Vivienne Poutney | ||||
2 | Reason for notification | |||||
a) | Position / status | Person closely associated of David Poutney | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Belluscura plc | ||||
b) | LEI | 213800BRJQZE56XBPW94 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 each in Belluscura plc ISIN: GB00BD3B8Z11 | ||||
b) | Nature of the transaction | Purchase of shares in SIPP | ||||
c) | Price(s) and volumes(s) |
| ||||
d) | Aggregated information | n/a | ||||
e) | Date of the transaction | 3 July 2024 | ||||
f) | Place of the transaction | London Stock Exchange |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.